What is NUVATION BIO?
NUVATION BIO is a global biopharmaceutical company dedicated to addressing the most difficult-to-treat cancers where conventional therapies have proven insufficient. The company focuses on developing differentiated and novel product candidates to tackle significant unmet needs in oncology, aiming to provide new therapeutic options for patients facing aggressive or resistant forms of cancer.
How much funding has NUVATION BIO raised?
NUVATION BIO has raised a total of $525M across 2 funding rounds:
Series A
$275M
Other Financing Round
$250M
Series A (2019): $275M with participation from Redmile Group, Perceptive Advisors, Surveyor Capital, The Baupost Group, Fidelity Management, ECOR1 Capital, Aisling Capital, Pavilion Capital, Omega Funds, EDBI, Altitude Life Science Ventures, and Boxer Capital
Other Financing Round (2025): $250M led by Sagard
Key Investors in NUVATION BIO
Redmile Group
Redmile Group LLC is a venture capital firm operating in the financial sector, known for its investments in innovative companies.
Perceptive Advisors
Perceptive Advisors is an investment firm based in New York, NY, focused on funding innovative healthcare and life sciences technologies.
The Baupost Group
The Baupost Group is an investment organization with a broad mandate, founded in 1982 and headquartered in Boston, Massachusetts.
What's next for NUVATION BIO?
The recent major strategic investment in NUVATION BIO signals a critical growth phase, likely enabling the company to advance its pipeline of oncology therapeutics through further research, clinical development, and potential commercialization efforts. This influx of capital is expected to accelerate its mission to bring innovative treatments to patients with limited options, reinforcing its commitment to tackling complex cancer challenges.
See full NUVATION BIO company page
